News Articles

175 Million Europeans Have Sleep Apnoea, Highlighting Scale of Global Health Crisis PARIS -Wednesday 19 September 2018

(BUSINESS WIRE)-- Roughly 175 million Europeans have obstructive sleep apnoea, according to a late-breaking abstract presented by ResMed today at the European Respiratory Society’s annual ERS Congress in Paris. Leading researchers estimate 90 million Europeans have moderate to severe sleep...

ResMed Introduces Its First Minimal-contact Full Face CPAP Mask, AirFit F30 -Friday 14 September 2018  

(BUSINESS WIRE)-- ResMed (NYSE: RMD) (ASX: RMD) today introduced its first minimal-contact full face CPAP mask, AirFit F30, the latest addition to its AirFit mask portfolio, which helps users reduce facial marks, wear glasses in bed and curl up closer to their bed partner. Unlike most...

ResMed Files Patent Infringement Action against Fisher & Paykel -Saturday 1 September 2018

(BUSINESS WIRE)-- ResMed (NYSE: RMD) (ASX: RMD), the world’s leading tech-driven medical device company and innovator in sleep apnea and respiratory care, today filed a petition with the United States International Trade Commission to stop the infringement of its patented technology by New...

ResMed’s Astral Life Support Ventilator Now Has AutoEPAP in U.S. -Tuesday 28 August 2018  

(BUSINESS WIRE)-- ResMed (NYSE: RMD) (ASX: RMD), a global leader in cloud-connected respiratory care devices, today announced key upgrades to its Astral life support ventilators, including Optional AutoEPAP in iVAPS for U.S. patients, a high-demand therapy option. What is...

ResMed, Verily to Form Joint Venture to Help Reach Millions of Untreated Sleep Apnea Sufferers -Thursday 12 July 2018  

(BUSINESS WIRE)-- ResMed (NYSE: RMD, ASX: RMD), a global leader in sleep apnea treatment and connected health solutions, and Verily, an Alphabet company, today announced their agreement to form a new joint venture. Combining ResMed’s expertise in sleep apnea and Verily’s advanced health...

New ResMed-sponsored Study Shows Switching to Bilevel PAP Saves 56% of Patients from Therapy Termination -Tuesday 5 June 2018

(BUSINESS WIRE)-- A new study reveals that shifting patients who are struggling with adherence to positive airway pressure (PAP) therapy to a more advanced bilevel device in the first 90 days of treatment is an effective tool for achieving adherence in well more than half of such cases. This...

ResMed to Acquire HEALTHCAREfirst, a Cloud-based Software and Services Provider for Home Health and Hospice Agencies -Wednesday 30 May 2018  

(BUSINESS WIRE) -- ResMed (NYSE:RMD, ASX:RMD), a global leader in connected healthcare solutions, today announced it has entered into a definitive agreement to acquire privately held HEALTHCAREfirst, a provider of software solutions and services for home health and hospice...

ResMed Studies Show Remote Monitoring and Automated Resupply Improve Adherence to PAP Therapy -Wednesday 23 May 2018

(BUSINESS WIRE)-- Remote patient monitoring and resupply programs have been shown to improve patient adherence to positive airway pressure (PAP) therapy, according to two separate studies presented by ResMed (NYSE: RMD, ASX: RMD) this week at the ATS 2018 International Conference. Remote...

Nearly 1 Billion People Worldwide Have Sleep Apnea, International Sleep Experts Estimate -Tuesday 22 May 2018  

(BUSINESS WIRE) -- A new data analysis presented by ResMed (NYSE: RMD, ASX: RMD) this week at the ATS 2018 International Conference indicates that the prevalence of sleep apnea impacts more than 936 million people worldwide – nearly 10 times greater than previous estimates. The study...

ResMed-sponsored Studies Show Combining Home Oxygen and Home Non-invasive Ventilation is a Cost Effective Treatment for... -Monday 21 May 2018

(BUSINESS WIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced today the results of two clinical analyses conducted for the U.K. and U.S., demonstrating the cost effectiveness of combining home oxygen therapy and home non-invasive ventilation (NIV) therapy for patients with persistent hypercapnia...

ResMed’s New QuietAir Diffuser Vent for CPAP Masks Reduces Noise by 89 Percent -Friday 11 May 2018  

(BUSINESS WIRE)-- ResMed (NYSE: RMD) (ASX: RMD) today introduced the QuietAir diffuser vent elbow, for its latest continuous positive airway pressure (CPAP) full face masks: AirFit F20 with silicone cushion and AirTouch F20 with memory foam cushion. QuietAir reduces noise by 89 percent and...

ResMed Hires Bobby Ghoshal as First Chief Technology Officer -Tuesday 3 April 2018  

(BUSINESS WIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the hire of its first chief technology officer (CTO), Bobby Ghoshal, effective today. As CTO, Ghoshal will lead ResMed’s global healthcare informatics and data analytics team to drive its world-leading cloud-based digital...

Results 1-12 of 12